Shopping Cart 0
Cart Subtotal
AED 0

Cough - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 22020

Details

Cough-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough-Pipeline Review, H1 2019, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 2, 11, 4, 9 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Introduction

Cough-Overview

Cough-Therapeutics Development

Cough-Therapeutics Assessment

Cough-Companies Involved in Therapeutics Development

Cough-Drug Profiles

Cough-Dormant Projects

Cough-Discontinued Products

Cough-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Cough, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Cough, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Cough-Pipeline by Alitair Pharmaceuticals Inc, H1 2019

Cough-Pipeline by Bayer AG, H1 2019

Cough-Pipeline by Beijing Tide Pharmaceutical Co Ltd, H1 2019

Cough-Pipeline by Charleston Laboratories Inc, H1 2019

Cough-Pipeline by Conrig Pharma ApS, H1 2019

Cough-Pipeline by Develco Pharma Schweiz AG, H1 2019

Cough-Pipeline by Evotec AG, H1 2019

Cough-Pipeline by Grunenthal GmbH, H1 2019

Cough-Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2019

Cough-Pipeline by Merck & Co Inc, H1 2019

Cough-Pipeline by Orbis Biosciences Inc, H1 2019

Cough-Pipeline by PhytoHealth Corp, H1 2019

Cough-Pipeline by Roivant Sciences Ltd, H1 2019

Cough-Pipeline by Shionogi & Co Ltd, H1 2019

Cough-Pipeline by SolAeroMed Inc, H1 2019

Cough-Pipeline by Tris Pharma Inc, H1 2019

Cough-Dormant Projects, H1 2019

Cough-Dormant Projects, H1 2019 (Contd..1), H1 2019

Cough-Discontinued Products, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Alitair Pharmaceuticals Inc

Bayer AG

Beijing Tide Pharmaceutical Co Ltd

Charleston Laboratories Inc

Conrig Pharma ApS

Develco Pharma Schweiz AG

Evotec AG

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Merck & Co Inc

Orbis Biosciences Inc

PhytoHealth Corp

Roivant Sciences Ltd

Shionogi & Co Ltd

SolAeroMed Inc

Tris Pharma Inc

Company Profile

Company Profile Title

Cough-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough-Pipeline Review, H1 2019, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 2, 11, 4, 9 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Introduction

Cough-Overview

Cough-Therapeutics Development

Cough-Therapeutics Assessment

Cough-Companies Involved in Therapeutics Development

Cough-Drug Profiles

Cough-Dormant Projects

Cough-Discontinued Products

Cough-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Cough, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Cough, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Cough-Pipeline by Alitair Pharmaceuticals Inc, H1 2019

Cough-Pipeline by Bayer AG, H1 2019

Cough-Pipeline by Beijing Tide Pharmaceutical Co Ltd, H1 2019

Cough-Pipeline by Charleston Laboratories Inc, H1 2019

Cough-Pipeline by Conrig Pharma ApS, H1 2019

Cough-Pipeline by Develco Pharma Schweiz AG, H1 2019

Cough-Pipeline by Evotec AG, H1 2019

Cough-Pipeline by Grunenthal GmbH, H1 2019

Cough-Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2019

Cough-Pipeline by Merck & Co Inc, H1 2019

Cough-Pipeline by Orbis Biosciences Inc, H1 2019

Cough-Pipeline by PhytoHealth Corp, H1 2019

Cough-Pipeline by Roivant Sciences Ltd, H1 2019

Cough-Pipeline by Shionogi & Co Ltd, H1 2019

Cough-Pipeline by SolAeroMed Inc, H1 2019

Cough-Pipeline by Tris Pharma Inc, H1 2019

Cough-Dormant Projects, H1 2019

Cough-Dormant Projects, H1 2019 (Contd..1), H1 2019

Cough-Discontinued Products, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Alitair Pharmaceuticals Inc

Bayer AG

Beijing Tide Pharmaceutical Co Ltd

Charleston Laboratories Inc

Conrig Pharma ApS

Develco Pharma Schweiz AG

Evotec AG

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Merck & Co Inc

Orbis Biosciences Inc

PhytoHealth Corp

Roivant Sciences Ltd

Shionogi & Co Ltd

SolAeroMed Inc

Tris Pharma Inc